John Haanen
Professor Translational immunotherapy of cancer
- Name
- Prof.dr. J.B.A.G. Haanen
- Telephone
- +31 71 526 3057
- j.haanen@nki.nl
- ORCID iD
- 0000-0001-5884-7704
John B.A.G. Haanen is professor by special appointment at the department of clinical oncology of the Leiden University Medical Center. In addition, John Haanen is Head of the Division of Medical Oncology at The Netherlands Cancer Institute in Amsterdam, The Netherlands.
More information about John Haanen
John B.A.G. Haanen is professor by special appointment at the department of clinical oncology of the Leiden University Medical Center. In addition, John Haanen is Head of the Division of Medical Oncology at The Netherlands Cancer Institute in Amsterdam, The Netherlands.
Immunotherapy
Immunotherapy can be considered the most important breakthrough in cancer treatment of the past 15 years. Unfortunately, despite this improvement only a fraction of patients benefit long-term. A better understanding of the mechanism of action of current immunotherapies and the way our immune system fights cancer, will lead to further improvement and more individualized ways of treatment. Translational research is necessary to reach these goals. My current focus in cancer immunotherapy is directed at novel cell therapy approaches for the treatment of solid cancers, including TIL, CAR-T and TCR-T.
Immunotherapy is a very costly treatment. More cost-effective use of immunotherapies also serves a societal purpose.
Academic career
Thesis defence: November 13, 1991: Functional analysis of Human Mycobacterium Leprae-specific CD4+ helper T cell clones.
Inaugural lecture endowed professorship Translational immunotherapy of cancer: October 2, 2009: On research with immune cells and multilingual doctors.
Professor Translational immunotherapy of cancer
- Faculteit Geneeskunde
- Divisie 4
- Klinische Oncologie
- Zeijl, M.C.T. van; Breeschoten, J. van; Wreede, L.C. de; Wouters, M.W.J.M.; Hilarius, D.L.; Blank, C.U.; Aarts, M.J.B.; Berkmortel, F.W.P.J. van den; Groot, J.W.B. de; Hospers, G.A.P.; Kapiteijn, E.; Piersma, D.; Rijn, R.S. van; Boer, M.A.S.D.; Veldt, A.A.M. van der; Vreugdenhil, G.; Boers-Sonderen, M.J.; Suijkerbuijk, K.P.M.; Haanen, J.B.A.G. & Eertwegh, A.J.M. van den (2023), Real-world outcomes of ipilimumab plus nivolumab combination therapy in a nationwide cohort of advanced melanoma patients in the Netherlands, Journal of Immunotherapy 46(5): 197-204.
- (2022), MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma, Immuno-Oncology and Technology 15.
- (2022), Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial, BMC Cancer 22.
- Rozeman, E.A.; Versluis, J.M.; Moritz, R.; Wilgenhof, S.; Thienen, J.V. van; Haanen, J.B.A.G.; Heuvel, M.M. van de; Blank, C.U. & Rossum, H.H. van (2022), Diagnostic performance of early increase in S100B or LDH as outcome predictor for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma, Clinica Chimica Acta.
- Reijers, I.L.M.; Menzies, A.M.; Akkooi, A.C.J. van; Versluis, J.M.; Heuvel, N.M.J. van den; Saw, R.P.M.; Pennington, T.E.; Kapiteijn, E.; Veldt, A.A.M. van der; Suijkerbuijk, K.P.M.; Hospers, G.A.P.; Rozeman, E.A.; Klop, W.M.C.; Houdt, W.J. van; Sikorska, K.; Hage, J.A. van der; Grunhagen, D.J.; Wouters, M.W.; Witkamp, A.J.; Zuur, C.L.; Lijnsvelt, J.M.; Acosta, A.T.; Grijpink-Ongering, L.G.; Gonzalez, M.; Jozwiak, K.; Bierman, C.; Shannon, K.F.; Ch'ng, S.; Colebatch, A.J.; Spillane, A.J.; Haanen, J.B.A.G.; Rawson, R.V.; Wiel, B.A. van de; Poll-franse, L.V. van de; Scolyer, R.A.; Boekhout, A.H.; Long, G.V. & Blank, C.U. (2022), Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial, Nature Medicine.
- Lindenberg, M.; Retel, V.; Rohaan, M.; Berg, J. van den; Haanen, J. & Harten, W. van (2020), Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectiveness , BMC Cancer 20.
- Trebeschi, S.; Drago, S.G.; Birkbak, N.J.; Kurilova, I.; Calin, A.M.; Pizzi, A.D.; Lalezari, F.; Lambregts, D.M.J.; Rohaan, M.W.; Parmar, C.; Rozeman, E.A.; Hartemink, K.J.; Swanton, C.; Haanen, J.B.A.G.; Blank, C.U.; Smit, E.F.; Beets-Tan, R.G.H. & Aerts, H.J.W.L. (2019), Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers , Annals of Oncology 30(6).
- Moel, E.C. de; Rozeman, E.A.; Kapiteijn, E.H.; Verdegaal, E.M.E.; Grummels, A.; Bakker, J.A.; Huizinga, T.W.J.; Haanen, J.B.; Toes, R.E.M. & Woude, D. van der (2019), Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors, Cancer Immunology Research 7(1): 6-11.
- Duinkerken, C.W.; Rohaan, F.W.; Weger, V.A. de; Lohuis, P.J.F.M.; Latenstein, M.N.; Theunissen, E.A.R.; Balm, A.J.M.; Dreschler, W.A.; Haanen, J.B.A.G. & Zuur, C.L. (2019), Sensorineural hearing loss after adoptive cell immunotherapy for melanoma using MART-1 specific T cells, Otology and Neurotology 40(7).
- Rohaan, M.W.; Wilgenhof, S. & Haanen, J.B.A.G. (2019), Adoptive cellular therapies: the current landscape, Virchows Archiv 474.
- Schouwenburg, M.G.; Jochems, A.; Leeneman, B.; Franken, M.G.; Eertwegh, A.J.M. van den; Haanen, J.B.A.G.; Zeijl, M.C.T. van; Aarts, M.J.; Akkooi, A.C.J. van; Berkmortel, F.W.P.J. van den; Blokx, W.A.M.; Groot, J.W.B. de; Hospers, G.A.P.; Kapiteijn, E.; Koornstra, R.H.; Kruit, W.H.; Louwman, M.W.J.; Piersma, D.; Rijn, R.S. van; Suijkerbuijk, K.P.M.; Tije, A.J. ten; Vreugdenhil, G.; Wouters, M.W.J.M. & Hoeven, J.J.M. van der (2018), Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes, Melanoma Research 28(4): 326-332.
- Franken, M.G.; Leeneman, B.; Jochems, A.; Schouwenburg, M.G.; Aarts, M.J.B.; Akkooi, A.C.J. van; Berkmortel, F.W.P.J. van den; Eertwegh, A.J.M. van den; Groot, J.W.B. de; Hoeven, K.J.M. van der; Hospers, G.A.P.; Kapiteijn, E.; Koornstra, R.; Kruit, W.H.J.; Louwman, M.W.J.; Piersma, D.; Rijn, R.S. van; Suijkerbuijk, K.P.M.; Tije, A.J. ten; Vreugdenhil, G.; Wouters, M.W.J.M.; Zeijl, M. van; Haanen, J.B.A.G. & Uyl-de Groot, C.A. (2018), Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands, Anti-Cancer Drugs 29(6): 579-588.
- Jochems, A.; Leeneman, B.; Franken, M.G.; Schouwenburg, M.G.; Aarts, M.J.B.; Akkooi, A.C.J. van; Berkmortel, F.W.P.J. van den; Eertwegh, A.J.M. van den; Groenewegen, G.; Groot, J.W.B. de; Haanen, J.B.A.G.; Hospers, G.A.P.; Kapiteijn, E.; Koornstra, R.H.; Kruit, W.H.J.; Louwman, M.W.J.; Piersma, D.; Rijn, R.S. van; Tije, A.J. ten; Vreugdenhil, G.; Wouters, M.W.J.M.; Uyl-de Groot, C.A. & Hoeven, K.J.M. van der (2018), Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands, Anti-Cancer Drugs 29(6): 572-578.
- Rohaan, M.W.; Berg, J.H. van den; Kvistborg, P. & Haanen, J.B.A.G. (2018), Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option, Journal for ImmunoTherapy of Cancer.
- Brouwer, N.J.; Haanen, J.B.A.G. & Jager, M.J. (2017), Development of Ocular Rosacea following Combined Ipilimumab and Nivolumab Treatment for Metastatic Malignant Skin Melanoma, Ocular Oncology and Pathology 3(3): 188-192.
- Franken, M.; Leeneman, B.; Jochems, A.; Schouwenburg, M.; Aarts, M.; Akkooi, A. van; Berkmortel, F. van den; Eertwegh, A. van den; Groot, J. de; Hoeven, J. van der; Hospers, G.; Kapiteijn, E.; Koornstra, R.; Kmit, W.; Louwman, M.; Piersma, D.; Rijn, R. van; Suijkerbuijk, K.; Tije, A. ten; Vreugdenhil, G.; Wouters, M.; Zeijl, M. van; Haanen, J. & Uyl-de Groot, C. (2017), HEALTHCARE COSTS OF IPILIMUMAB IN PATIENTS WITH ADVANCED CUTANEOUS MELANOMA IN DUTCH CLINICAL PRACTICE, Value in Health 20(9): A431-A431.
- Rozeman, E.A.; Prevoo, W.; Meier, M.A.J.; Sikorska, K.; Wiel, B.A. van de; Broeks, A.; Tinteren, H. van; Kapiteijn, E.; Thienen, J.V.; Haanen, J.B. & Blank, C.U. (2017), Combined radiofrequency ablation and ipilimumab in uveal melanoma: Results from the SECIRA-UM trial, Annals of Oncology 28.
- Samuels, S.; Heeren, A.M.; Zijlmans, H.J.M.A.A.; Welters, M.J.P.; Berg, J.H. van den; Philips, D.; Kvistborg, P.; Ehsan, I.; Scholl, S.M.E.; Nuijen, B.; Schumacher, T.N.M.; Beurden, M. van; Jordanova, E.S.; Haanen, J.B.A.G.; Burg, S.H. van der & Kenter, G.G. (2017), HPV16 E7 DNA tattooing: safety, immunogenicity, and clinical response in patients with HPV-positive vulvar intraepithelial neoplasia, Cancer Immunology, Immunotherapy 66(9): 1163-1173.
- Zeijl, M.C.T. van; Eertwegh, A.J. van den; Haanen, J.B. & Wouters, M.W.J.M. (2017), (Neo)adjuvant systemic therapy for melanoma, EJSO - European Journal of Surgical Oncology 43(3): 534-543.
- Jochems, A.; Schouwenburg, M.G.; Leeneman, B.; Franken, M.G.; Eertwegh, A.J.M. van den; Haanen, J.B.A.G.; Gelderblom, H.; Uyl-de Groot, C.A.; Aarts, M.J.B.; Berkmortel, F.W.P.J. van den; Blokx, W.A.M.; Cardous-Ubbink, M.C.; Groenewegen, G.; Groot, J.W.B. de; Hospers, G.A.P.; Kapiteijn, E.; Koornstra, R.H.; Kruit, W.H.; Louwman, M.W.; Piersma, D.; Rijn, R.S. van; Tije, A.J. ten; Vreugdenhil, G.; Wouters, M.W.J.M. & Hoeven, J.J.M. van der (2017), Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands, European Journal of Cancer 72: 156-165.
- Badrising, S.K.; Noort, V. van der; Hamberg, P.; Coenen, J.L.L.M.; Aarts, M.J.; Oort, I.M. van; Eertwegh, A.J.M. van den; , M. los; Berg, H.P. van den; Gelderblom, H.; Vrijaldenhoven, S.; Kerver, E.D.; Voorthuizen, T. van; Jong, I.J. de; Haanen, J.B.; Bergman, A.M. & Dutch Uro-Oncol Study Grp DUOS (2016), Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer, Oncology 91(5): 267-273.
- Verdegaal, E.M.E.; Miranda, N.F.C.C. de; Visser, M.; Harryvan, T.; Buuren, M.M. van; Andersen, R.S.; Hadrup, S.R.; Minne, C.E. van der; Schotte, R.; Spits, H.; Haanen, J.B.A.G.; Kapiteijn, E.H.W.; Schumacher, T.N. & Burg, S.H. van der (2016), Neoantigen landscape dynamics during human melanoma-T cell interactions, Nature 536(7614): 91-+.
- Badrising, S.K.; Noort, V. van der; Eertwegh, A.J.M. van den; Hamberg, P.; Oort, I.M. van; Berg, H.P. van den; , M. los; Aarts, M.J.B.; Coenen, J.L.L.M.; Gelderblom, H.; Jong, I.J. de; Kerver, E.D.; Vrijaldenhoven, S.; Voorthuizen, T. van; Warmerdam, F.; Haanen, J.B.; Bergman, A.M. & DUOS (2016), Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer, Oncology 91(5).
- Badrising, S.K.; Noort, V. van der; Eertwegh, A.J.M. van den; Hamberg, P.; Oort, I.M. van; Berg, H.P. van den; , M. los; Aarts, M.J.B.; Coenen, J.L.L.M.; Gelderblom, H.; Jong, I.J. de; Kerver, E.D.; Vrijaldenhoven, S.; Voorthuizen, T. van; Warmerdam, F.; Haanen, J.B.; Bergman, A.M. & DUOS (2016), Prognostic Parameters for Response to Enzalutamide After Docetaxel and Abiraterone Treatment in Metastatic Castration-Resistant Prostate Cancer Patients; a Possible Time Relation, Prostate 76(1): 32-40.
- Badrising, S.K.; Noort, V. van der; Eertwegh, A.J.M. van den; Hamberg, P.; Oort, I.M. van; Berg, H.P. van den; , M. los; Aarts, M.J.B.; Coenen, J.L.L.M.; Gelderblom, H.; Jong, I.J. de; Kerver, E.D.; Vrijaldenhoven, S.; Voorthuizen, T. van; Warmerdam, F.; Haanen, J.B.; Bergman, A.M. & DUOS (2016), Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castrationāresistant prostate cancer patients; a possible time relation, Prostate 76(1).
- Kvistborg, P.; Philips, D.; Kelderman, S.; Hageman, L.; Ottensmeier, C.; Joseph-Pietras, D.; Welters, M.J.P.; Burg, S. van der; Kapiteijn, E.; Michielin, O.; Romano, E.; Linnemann, C.; Speiser, D.; Blank, C.; Haanen, J.B. & Schumacher, T.N. (2014), Anti-CTLA-4 therapy broadens the melanoma-reactive CD8(+) T cell response, Science Translational Medicine 6(254).
- Tjin, E.P.M.; Krebbers, G.; Meijlink, K.J.; Kasteele, W. van de; Rosenberg, E.H.; Sanders, J.; Nederlof, P.M.; Wiel, B.A. van de; Haanen, J.B.A.G.; Melief, C.J.M.; Vyth-Dreese, F.A. & Luiten, R.M. (2014), Immune-Escape Markers in Relation to Clinical Outcome of Advanced Melanoma Patients Following Immunotherapy, Cancer Immunology Research 2(6): 538-546.
- Kelderman, S.; Heemskerk, B.; Tinteren, H. van; Brom, R.R.H. van den; Hospers, G.A.P.; Eertwegh, A.J.M. van den; Kapiteijn, E.W.; Groot, J.W.B. de; Soetekouw, P.; Jansen, R.L.; Fiets, E.; Furness, A.J.S.; Renn, A.; Krzystanek, M.; Szallasi, Z.; Lorigan, P.; Gore, M.E.; Schumacher, T.N.M.; Haanen, J.B.A.G.; Larkin, J.M.G. & Blank, C.U. (2014), Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma, Cancer Immunology, Immunotherapy 63(5): 449-458.
- Linnemann, C.; Heemskerk, B.; Kvistborg, P.; Kluin, R.J.C.; Bolotin, D.A.; Chen, X.J.; Bresser, K.; Nieuwland, M.; Schotte, R.; Michels, S.; Gomez-Eerland, R.; Jahn, L.; Hombrink, P.; Legrand, N.; Shu, C.J.; Mamedov, I.Z.; Velds, A.; Blank, C.U.; Haanen, J.B.A.G.; Turchaninova, M.A.; Kerkhoven, R.M.; Spits, H.; Hadrup, S.R.; Heemskerk, M.H.M.; Blankenstein, T.; Chudakov, D.M.; Bendle, G.M. & Schumacher, T.N.M. (2013), High-throughput identification of antigen-specific TCRs by TCR gene capture, Nature Medicine 19(11): 1534-+.
- Blank, C.U.; Kelderman, S.; Tinteren, H. van; Heemskerk, B.; Brom, R. van den; Hospers, G.A.; Eertwegh, A.J.M. van den; Kapiteijn, E.; Groot, J.W. de; Jansen, R.L.; Fiets, W.E.; Krzystanek, M.; Szallasi, Z.; Furness, A.J.S.; Renn, A.; Gore, M.E.; Lorigan, P.; Schumacher, T.; Haanen, J.B.A.G. & Larkin, J.M.G. (2013), Serum lactate dehydrogenase (LDH) as a prognostic selection criterion for ipilimumab treatment in metastatic melanoma, Journal of Clinical Oncology 31(15).
- Eechoute, K.; Veldt, A.A.M. van der; Oosting, S.; Kappers, M.H.W.; Wessels, J.A.M.; Gelderblom, H.; Guchelaar, H.J.; Reyners, A.K.L.; Herpen, C.M.L. van; Haanen, J.B.; Mathijssen, R.H.J. & , E. boven (2012), Polymorphisms in Endothelial Nitric Oxide Synthase (eNOS) and Vascular Endothelial Growth Factor (VEGF) Predict Sunitinib-Induced Hypertension.
- Verdegaal, E.M.E.; Visser, M.; Ramwadhdoebe, T.H.; Minne, C.E. van der; Steijn, J.A.Q.M.J. van; Kapiteijn, E.; Haanen, J.B.A.G.; Burg, S.H. van der; Nortier, J.W.R. & Osanto, S. (2011), Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+and CD8+T cells in combination with low-dose interferon-alpha, Cancer Immunology, Immunotherapy 60(7): 953-963.
- Erp, N.P. van; Mathijssen, R.H.J.; Veldt, A.A. van der; Haanen, J.B.; Reyners, A.K.L.; Eechoute, K.; , E. boven; Wessels, J.A.M.; Guchelaar, H.J. & Gelderblom, H. (2010), Myelosuppression by sunitinib is flt-3 genotype dependent, British Journal of Cancer 103(5): 757-758.
- van Erp NP, Eechoute K, van der Veldt AA, Haanen JB, Reyners AKL, Mathijssen RHJ, Boven E, van der Straaten T, Baak-Pablo RF, Wessels JAM, Guchelaar HJ & Gelderblom H (2009), Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity, Journal of Clinical Oncology 27(26): 4406-4412.
- Bos, R.; Duikeren, S. van; Morreau, H.; Franken, K.; Schumacher, T.N.M.; Haanen, J.B.; Burg, S.H.D.; Melief, C.J.M. & Offringa, R. (2008), Balancing between Antitumor Efficacy and Autoimmune Pathology in T-Cell-Mediated Targeting of Carcinoembryonic Antigen, Cancer Research 68(20).
- Jorritsma A, Gomez-Eerland R, Dokter M, van de Kasteele W, Zoet YM, Doxiadis IIN, Rufer N, Romero P, Morgan RA, Schumacher TNM & Haanen JBAG (2007), Selecting highly affine and well-expressed TCRs for gene therapy of melanoma, Blood 110(10).
- Vyth-Dreese FA, Kim YH, Dellemijn TAM, Schrama E, Haanen JBAG, Spierings E & Goulmy E (2006), In situ visualization of antigen-specific T cells in cryopreserved human tissues, Journal of Immunological Methods 310(1-2).
- Dickinson AM, Wang XN, Sviland L, Vyth-Dreese FA, Jackson GH, Schumacher TNM, Haanen JBAG, Mutis T & Goulmy E (2002), In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens, Nature Medicine 8(4).
No relevant ancillary activities